Onyema Ogbuagu
Overview
Explore the profile of Onyema Ogbuagu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1278
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Margot N, Jogiraju V, Pennetzdorfer N, Naik V, VanderVeen L, Ling J, et al.
J Infect Dis
. 2025 Jan;
PMID: 39873394
Background: Lenacapavir is a highly potent first-in-class inhibitor of HIV-1 capsid approved for the treatment of heavily treatment-experienced (HTE) people with HIV-1 (PWH) harboring multidrug resistant (MDR) virus, in combination...
2.
Okoli A, Ogbuagu O
Expert Opin Drug Metab Toxicol
. 2025 Jan;
1-15.
PMID: 39836520
Introduction: Background: People with HIV (PWH) have benefited tremendously from effective antiretroviral(ARV) treatments. However, PWH are at increased risk for other viral infections transmitted in the same way as HIV...
3.
Kelley C, Acevedo-Quinones M, Agwu A, Avihingsanon A, Benson P, Blumenthal J, et al.
N Engl J Med
. 2024 Nov;
PMID: 39602624
Background: Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgender men, transgender...
4.
Seethamraju H, Yang O, Loftus R, Ogbuagu O, Sammartino D, Mansour A, et al.
Clin Ther
. 2024 Oct;
46(11):891-899.
PMID: 39353749
Purpose: Early in the course of the SARS-CoV-2 pandemic it was hypothesised that host genetics played a role in the pathophysiology of COVID-19 including a suggestion that the CCR5-Δ32 mutation...
5.
Tuan J, Igiraneza G, Ogbuagu O
Expert Opin Drug Metab Toxicol
. 2024 Sep;
20(10):953-965.
PMID: 39230187
Background: People with HIV (PWH) are living longer directly related to benefits of highly effective antiretroviral therapy (ART). However, concurrent with improved longevity is the growing prevalence of metabolic comorbidities...
6.
Ogbuagu O, Molina J, Chetchotisakd P, Ramgopal M, Sanchez W, Brunetta J, et al.
Clin Infect Dis
. 2024 Aug;
PMID: 39206943
Background: Lenacapavir is a long-acting HIV-1 capsid inhibitor for treatment of HIV-1 infection. We evaluated the efficacy and safety of lenacapavir in combination with an investigator-selected optimized background regimen (OBR)...
7.
Strong S, Oldfield B, Berg J, Cole C, Biegacki E, Ogbuagu O, et al.
Prev Med Rep
. 2024 Jan;
37:102553.
PMID: 38282665
Unhealthy alcohol use is a common, often unaddressed behavior associated with increased risk for acquisition of HIV and may also be associated with decreased adherence to oral pre-exposure prophylaxis (PrEP)...
8.
Tuan J, Okoli A, Ogbuagu O
Expert Opin Drug Metab Toxicol
. 2023 Dec;
19(12):881-888.
PMID: 38058292
Introduction: The World Health Organization proposed targets to eliminate hepatitis C virus (HCV) by 2030, aiming to treat ≥80% of people with HCV, decreasing new chronic infections by 90% and...
9.
Oyeyemi D, Chan E, Montano M, Belzer A, Ogbuagu O, Zapata H, et al.
J Med Case Rep
. 2023 Nov;
17(1):489.
PMID: 37946248
Background: We present a case report of an immunocompetent host with presumed sexually transmitted cytomegalovirus proctitis and epididymitis, where there currently is a sparsity of published data. Case Presentation: A...
10.
Mohammed A, Idris-Dantata H, Okwor T, Tanui P, Paintsil E, Kabwe P, et al.
Glob Health Sci Pract
. 2023 Oct;
11(5).
PMID: 37903581
No abstract available.